Neurocrine Biosciences | Los Gastos Financieros De La Deuda



Interest Expense On Debt Cambio Fecha
AbbVie USD 700M 90M 2025-03
Acadia Pharmaceuticals 0 4.12M 2024-09
Agios Pharmaceuticals 3.01M 10.05M 2024-12
ALKERMES USD 0 0 2025-06
Alnylam Pharmaceuticals USD 40.25M 1.6M 2025-06
Amgen USD 694M 29M 2025-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.68M 184K 2025-06
Cytokinetics USD 22.95M 352K 2025-03
Dynavax Technologies USD 1.69M 12K 2025-03
Exelixis 23.4M 3.9M 2023-09
Gilead Sciences USD 260M 12M 2025-03
Halozyme Therapeutics USD 4.39M 131K 2025-06
Incyte USD 594K 66K 2025-06
Ionis Pharmaceuticals USD 19M 0 2025-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 654M 0 2025-06
Prothena 0 0 2024-06
Regeneron Pharmaceuticals USD 3.6M 5.1M 2025-06
Repligen USD 5.35M 104K 2025-06
Sarepta Therapeutics USD 5.23M 725K 2025-06
Teva Pharmaceutical Industries USD 252M 40M 2025-06
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Vertex Pharmaceuticals USD 3.7M 900K 2025-06


Neurocrine Biosciences Los Gastos Financieros De La Deuda - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.